Engineering the rRNA decoding site of eukaryotic cytosolic ribosomes in bacteria.
Structural and genetic studies on prokaryotic ribosomes have provided important insights into fundamental aspects of protein synthesis and translational control and its interaction with ribosomal drugs. Comparable mechanistic studies in eukaryotes are mainly hampered by the absence of both high-resolution crystal structures and efficient genetic models. To study the interaction of aminoglycoside antibiotics with selected eukaryotic ribosomes, we replaced the bacterial drug binding site in 16S rRNA with its eukaryotic counterpart, resulting in bacterial hybrid ribosomes with a fully functional eukaryotic rRNA decoding site. Cell-free translation assays demonstrated that hybrid ribosomes carrying the rRNA decoding site of higher eukaryotes show pronounced resistance to aminoglycoside antibiotics, equivalent to that of rabbit reticulocyte ribosomes, while the decoding sites of parasitic protozoa show distinctive drug susceptibility. Our findings suggest that phylogenetically variable components of the ribosome, other than the rRNA-binding site, do not affect aminoglycoside susceptibility of the protein-synthesis machinery. The activities of the hybrid ribosomes indicate that helix 44 of the rRNA decoding site behaves as an autonomous domain, which can be exchanged between ribosomes of different phylogenetic domains for study of function.
Hobbie
Sven N
SN
Institut für Medizinische Mikrobiologie, Universität Zürich and Laboratorium für Organische Chemie, ETH Zürich, Switzerland. shobbie@immv.uzh.ch
Kalapala
Sarath K
SK
Akshay
Subramanian
S
Bruell
Christian
C
Schmidt
Sebastian
S
Dabow
Sabine
S
Vasella
Andrea
A
Sander
Peter
P
Böttger
Erik C
EC
D000617:Aminoglycosides / Q000494:pharmacology*; D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D001483:Base Sequence; D003600:Cytosol / Q000378:metabolism; D032621:DNA Shuffling; D005057:Eukaryotic Cells / Q000378:metabolism; D005815:Genetic Code; D006801:Humans; D008969:Molecular Sequence Data; D009154:Mutation; D020102:Mycobacterium smegmatis / Q000235:genetics; D014176:Protein Biosynthesis / Q000187:drug effects; D011500:Protein Synthesis Inhibitors / Q000494:pharmacology*; D012336:RNA, Ribosomal, 16S / Q000737:chemistry* / Q000187:drug effects; D012270:Ribosomes / Q000737:chemistry / Q000187:drug effects* / Q000378:metabolism
D000617:Aminoglycosides; D000900:Anti-Bacterial Agents; D011500:Protein Synthesis Inhibitors; D012336:RNA, Ribosomal, 16S